Sprycel (Prostate Cancer) - Forecast and Market Analysis to 2022


#163796

54pages

GlobalData

$ 6995

In Stock

Sprycel (Prostate Cancer) - Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Sprycel (Prostate Cancer) - Forecast and Market Analysis to 2022”. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide) will drive strong market growth over the next decade. 

These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. 

For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

BMS’ Sprycel is in development for use in combination with docetaxel and prednisone as a first-line treatment for mCRPC. It is currently approved for the treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). Sprycel is small-molecule kinase inhibitor administered orally once daily that inhibits the activity of BCR-ABL and the SRC family of kinases, as well as c-KIT, EPHA2, and PDGFR?.

Scope
  • Overview of Prostate cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Sprycel including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Sprycel for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Sprycel performance 
  • Obtain sales forecast for Sprycel from 2012-2022 in nine markets (US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia)
Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6

2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 7
2.3 Upcoming Related Reports 9

3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 10
3.1.3 Prognosis 11
3.1.4 Quality of Life 12
3.2 Symptoms 12

4 Disease Management 13
4.1 Diagnosis and Referral Overview 13
4.2 Treatment Overview 15
4.2.1 Conservative Management Strategies 19
4.2.2 Localized Treatments 20
4.2.3 Hormone Therapy 21
4.2.4 Drug Therapies 23

5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26

6 Opportunity and Unmet Need 29
6.1 Overview 29
6.2 Efficacy at Prolonging Overall Survival 30
6.3 Safety 30
6.4 Mitigation of Symptoms 31
6.5 Cost 31
6.6 Convenient Routes of Administration 31
6.7 Accurate Diagnostic Tests and Surveillance Tools 32
6.8 Unmet Needs Gap Analysis 32
6.9 Opportunity: Targeting Early-Stage, Hormone-Sensitive Prostate Cancer 33

7 Pipeline Assessment 34
7.1 Overview 34
7.2 Promising Drugs in Clinical Development 35

8 Sprycel (dasatinib) 37
8.1 Overview 37
8.2 Efficacy 38
8.3 Safety 38
8.4 Dosing and Formulation 38
8.5 Potential Clinical Positioning 39
8.6 Potential Commercial Positioning 39
8.7 Pricing and Reimbursement 40
8.8 SWOT Analysis 40
8.9 Forecast 41

9 Appendix 42
9.1 Bibliography 42
9.2 Abbreviations 46
9.3 Methodology 47
9.4 Forecasting Methodology 47
9.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment 48
9.4.2 Percent Drug-treated Patients 48
9.4.3 Percent Hormone Therapy-Treated Patients 48
9.4.4 General Pricing Assumptions 49
9.4.5 Individual Drug Assumptions 51
9.4.6 Generic Erosion 51
9.4.7 Pricing of Pipeline Agents 51
9.5 Physicians and Specialists Included in This Study 52
9.6 Survey of Prescribing Physicians 52
9.7 About the Authors 53
9.7.1 Authors 53
9.7.2 Global Head of Healthcare 53
9.8 About GlobalData 54
9.9 Contact Us 54
9.10 Disclaimer 54

Table 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets 11
Table 2: Global Variations in Recommendations on Routine PSA Screening 13
Table 3: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 2012 16
Table 4: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets, 2012 18
Table 5: Leading Treatments for Prostate Cancer, 2012 28
Table 6: Overall Unmet Needs, Hormone-Sensitive Prostate Cancer - Current Level of Attainment 29
Table 7: Overall Unmet Needs, CRPC - Current Level of Attainment 30
Table 8: Clinical Unmet Needs - Gap Analysis, 2012 33
Table 9: Prostate Cancer - Phase III Pipeline, 2012 35
Table 10: Comparison of Therapeutic Classes in Development for Prostate Cancer, 2012 35
Table 11: Product Profile - Sprycel 37
Table 12: Sprycel SWOT Analysis, 2012 41
Table 13: Global Sales Forecasts ($m) for Sprycel, 2012-2022 41
Table 14: Physicians Surveyed, By Country 52
Figure 1: General Treatment Algorithm for Prostate Cancer, 2012 17
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2012-2022 36